SciSparc Subsidiary NeuroThera Granted Japanese Patent for Drug Combination
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., has been granted a patent by the Japanese Patent Office. The patent, titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols," covers pharmaceutical combinations designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies, including paracetamol. This development strengthens NeuroThera's intellectual property portfolio, potentially allowing lower effective dosing and mitigating side effects, and marks a strategic milestone for advancing its therapeutic innovations globally. SciSparc, through NeuroThera, focuses on cannabinoid pharmaceuticals and other drug development programs.
Key Highlights
- SciSparc's majority-owned subsidiary, NeuroThera Labs Inc., granted Japanese patent.
- Patent titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols."
- Covers combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines.
- Designed to enhance analgesic and antipyretic performance of 4-aminophenol-based therapies.
- Aims to enable lower effective dosing and mitigate dose-related side effects.
- Strengthens NeuroThera's intellectual property portfolio for combination-therapy platforms.
- Marks an important strategic milestone for global market advancement of therapeutic innovations.
Price Impact
More from SPRC